Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SRK-001 in Healthy Participants
NCT05156034Phase 1Terminated
- Sponsor
- Sarkana Pharma, Inc.
- Start
- Dec 2021
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3200327 in systemic lupus erythematosus (SLE) (4 arms), sponsored by Sarkana Pharma, Inc. Primary endpoint: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs). Started Dec 2021; status: terminated.
02
Drugs
LY3200327
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05156034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05156034.